Publications by authors named "Ulf G Eriksson"

Claim this Profile
P
Proof of lung muscarinic receptor occupancy by tiotropium: Translational Positron Emission Tomography studies in non-human primates and humans.
Zsolt Cselényi, Aurelija Jucaite, Pär Ewing, Per Stenkrona, Cecilia Kristensson, Ulf G Eriksson

Front Nucl Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers.
Susanne Prothon, Magnus Aurivillius, Ulrika Tehler, Ulf G Eriksson, Ajay Aggarwal

Drug Des Devel Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A stochastic mixed effects model to assess treatment effects and fluctuations in home-measured peak expiratory flow and the association with exacerbation risk in asthma.
Jacob Leander, Mats Jirstrand, Ulf G Eriksson, Robert Palmér

CPT Pharmacometrics Syst Pharmacol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation.
Muhammad Waqas Sadiq, Olaf Holz, Birthe D Ellinghusen, Cornelia Faulenbach, Meike Müller, Ulf G Eriksson

Br J Pharmacol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases.
Jacob Leander, Mikael Sunnåker, Dinko Rekić, Sergey Aksenov, Ulf G Eriksson

J Pharmacokinet Pharmacodyn· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal FEV and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling.
Kirill Zhudenkov, Robert Palmér, Alexandra Jauhiainen, Gabriel Helmlinger, Oleg Stepanov, Ulf G Eriksson

Int J Chron Obstruct Pulmon Dis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of Equipotent Doses for Anti-Inflammatory Effects of Prednisolone and AZD9567, an Oral Selective Nonsteroidal Glucocorticoid Receptor Modulator.
Joachim Almquist, Muhammad Waqas Sadiq, Ulf G Eriksson, Tove Hegelund Myrbäck, Susanne Prothon

CPT Pharmacometrics Syst Pharmacol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification and reliability of [C]VC - 002 binding to muscarinic acetylcholine receptors in the human lung - a test-retest PET study in control subjects.
Zsolt Cselényi, Aurelija Jucaite, Cecilia Kristensson, Per Stenkrona, Pär Ewing, Ulf G Eriksson

EJNMMI Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the evaluation of COPD exacerbation treatment effects by accounting for early treatment discontinuations: a post-hoc analysis of randomized clinical trials.
Agnieszka Król, Robert Palmér, Virginie Rondeau, Stephen Rennard, Ulf G Eriksson

Respir Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials.
Tove Hegelund Myrbäck, Susanne Prothon, Karl Edman, Jacob Leander, Mahdi Hashemi, Ulf G Eriksson

Lancet Rheumatol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational modeling of lung deposition of inhaled particles in chronic obstructive pulmonary disease (COPD) patients: identification of gaps in knowledge and data.
Koustav Ganguly, Ulrika Carlander, Estella Dg Garessus, Markus Fridén, Ulf G Eriksson

Crit Rev Toxicol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
Sergey Aksenov, Carl C Peck, Ulf G Eriksson, Donald R Stanski

Physiol Rep· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.
Gregory Y H Lip, Lars H Rasmussen, S Bertil Olsson, Eva Jensen, Bengt Hamrén, Ulf G Eriksson

Br J Clin Pharmacol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel in vivo receptor occupancy methodology for the glucocorticoid receptor: toward an improved understanding of lung pharmacokinetic/pharmacodynamic relationships.
Elin Boger, Pär Ewing, Ulf G Eriksson, Britt-Marie Fihn, Michael Chappell

J Pharmacol Exp Ther· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined in vitro-in vivo approach to assess the hepatobiliary disposition of a novel oral thrombin inhibitor.
Elin M Matsson, Ulf G Eriksson, Johan E Palm, Per Artursson, Maria Karlgren

Mol Pharm· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral ximelagatran : a multicentre study of thromboprophylaxis in elective abdominal surgery.
David Bergqvist, Jan-Helge Solhaug, Lena Holmdahl, Ulf G Eriksson, Magnus Andersson

Clin Drug Investig· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No influence of food on the pharmacokinetics, pharmacodynamics or tolerability of the 24mg and 36mg oral tablet formulations of ximelagatran.
Eva Ersdal, Kajs-Marie Schützer, Carina Lönnerstedt, Lis Ohlsson, Ulrika Wall, Ulf G Eriksson

Clin Drug Investig· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.
Michael Wolzt, Ulf G Eriksson, Ghazaleh Gouya, Nicolai Leuchten, Stylianos Kapiotis

Thromb Res· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations.
Martin Bergstrand, Erik Söderlind, Ulf G Eriksson, Werner Weitschies, Mats O Karlsson

Pharm Res· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations.
Martin Bergstrand, Erik Söderlind, Ulf G Eriksson, Werner Weitschies, Mats O Karlsson

Pharm Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biliary excretion of ximelagatran and its metabolites and the influence of erythromycin following intraintestinal administration to healthy volunteers.
Elin M Matsson, Ulf G Eriksson, Lars Knutson, Kurt-Jürgen Hoffmann, Ulrika Logren

J Clin Pharmacol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ketoconazole on the in vivo biotransformation and hepatobiliary transport of the thrombin inhibitor AZD0837 in pigs.
Elin M Matsson, Johan E Palm, Ulf G Eriksson, Pernilla Bottner, Anna Lundahl

Drug Metab Dispos· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837.
Kajs-Marie Schützer, Maria K Svensson, Sofia Zetterstrand, Ulf G Eriksson, Karin Wåhlander

Eur J Clin Pharmacol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs.
Elin Sjödin, Holger Fritsch, Ulf G Eriksson, Ulrika Logren, Anders Nordgren

Drug Metab Dispos· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers.
Hassan Dorani, Kajs-Marie Schützer, Troy C Sarich, Ulrika Wall, Ulrika Logren, Ulf G Eriksson

Eur J Clin Pharmacol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis